Abstract: In certain aspects, provided herein are inhibitory anti-ENPP1 antibodies and antigen binding fragments thereof. In some aspects, provided herein are methods of treating myocardial infarction using the antibodies provided herein. In certain aspects, provided herein are nucleic acid molecules encoding the antibodies provided herein, host cells comprising such nucleic acids, and methods of making the antibodies provided herein using such host cells. In some aspects, also provided herein are pharmaceutical compositions comprising the antibodies provided herein.

Abstract: Provided herein are methods and compositions related to monitoring ENPP1 activity and the treatment of cardiac injury using pyrimidine nucleotides.

Abstract: In certain aspects, provided herein are inhibitory anti-ENPP1 antibodies and antigen binding fragments thereof. In some aspects, provided herein are methods of treating myocardial infarction using the antibodies provided herein. In certain aspects, provided herein are nucleic acid molecules encoding the antibodies provided herein, host cells comprising such nucleic acids, and methods of making the antibodies provided herein using such host cells. In some aspects, also provided herein are pharmaceutical compositions comprising the antibodies provided herein.

Abstract: The present disclosure relates to compounds that are capable of inhibiting the ENPP1 gene and treating a variety of cardiac conditions. The disclosure further relates to methods of treating or preventing cardiac conditions, such as myocardial infarction and heart failure.

Abstract: Disclosed herein are methods for inhibiting ectopic calcification in soft tissues, such as heart tissue. Also provided herein are ectonucleotide pyrophosphatase/phosphodiesterase-1 (ENPP1) inhibitors.

Abstract: The present disclosure relates to compositions and methods for treating a dysregulated wound healing, for improving wound healing, for inhibiting scar formation, for treating a subject with Ehlers Danlos syndrome (EDS), and for treating a subject diagnosed with a heart attack. The present disclosure further relates to compositions and methods for predicting future cardiac risk in a subject who has suffered a heart attack, and predicting risk of future cardiac disease in a subject suffering a heart attack.

Abstract: Disclosed herein are methods for treating cardiac injury in a subject, comprising administering an ENPP1 inhibitor. Also disclosed are methods of promoting healing of cardiac tissue in a subject having a cardiac injury, comprising administering an ENPP1 inhibitor. Also disclosed are methods of inhibiting ATP hydrolysis in a cardiac fibroblast the method comprising contacting the cardiac fibroblast with an ENPP1 inhibitor. Also provided herein are ectonucleotide pyrophosphatase/phosphodiesterase-1 (ENPP1) inhibitors.

Abstract: Disclosed herein are methods for treating an ocular pathology in a subject, comprising administering to the subject an ENPP1 inhibitor. Also disclosed are methods of inhibiting ATP hydrolysis in ocular tissue, the method comprising contacting the ocular tissue with an ENPP1 inhibitor. Also provided herein are ectonucleotide pyrophosphatase/phosphodiesterase-1 (ENPP1) inhibitors and compositions comprising the same.

Abstract: In certain aspects, provided herein are inhibitory anti-ENPP1 antibodies and antigen binding fragments thereof. In some aspects, provided herein are methods of treating myocardial infarction using the antibodies provided herein. In certain aspects, provided herein are nucleic acid molecules encoding the antibodies provided herein, host cells comprising such nucleic acids, and methods of making the antibodies provided herein using such host cells. In some aspects, also provided herein are pharmaceutical compositions comprising the antibodies provided herein.

Abstract: Disclosed herein are methods for inhibiting ectopic calcification in soft tissues, such as heart tissue. Also provided herein are ectonucleotide pyrophosphatase/phosphodiesterase-1 (ENPP1) inhibitors.

Abstract: Disclosed herein are methods for inhibiting ectopic calcification in soft tissues, such as heart tissue. Also provided herein are ectonucleotide pyrophosphatase/phosphodiesterase-1 (ENPP1) inhibitors.

Abstract: The present invention relates to the discovery of the role of Wnt1 in multiple cardiovascular processes, including cardiac repair, angiogenesis, and stimulation of endothelial progenitor cells. This discovery provides methods of using Wnt1 to treat cardiovascular disorders and injuries.

Abstract: The present invention relates to the discovery of the role of Wnt1 in multiple cardiovascular processes, including cardiac repair, angiogenesis, and stimulation of endothelial progenitor cells. This discovery provides methods of using Wnt1 to treat cardiovascular disorders and injuries.